Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Nipocalimab vs Efgartigimod in Generalized Myasthenia Gravis
NCT07217587Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07217587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217587.